Novo Must Face Mylan Challenge to Wegovy, Ozempic Patent (2)

Mylan Pharmaceuticals Inc. persuaded a US Patent and Trademark Office administrative tribunal to take up one of its challenges to Novo Nordisk A/S patents linked to the lucrative weight-loss drugs Ozempic and Wegovy.

The granted petition for inter partes review at the Patent and Trial Board represents a broadside to two drugs that combined to account for almost a quarter of Novo Nordisk’s 2022 revenue.

The PTAB instituted IPR of Novo Nordisk’s US Patent No. 10,335,462 on Wednesday, saying Mylan sufficiently argued that some of the patent’s claims were likely anticipated by and obvious in light of previous inventions. The ...